Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Phillip Garfin
Seagen Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- University of Southern California
Los Angeles, California, United States
- Rocky Mountain Cancer Centers, Llp
Aurora, Colorado, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- University of Colorado Hospital
Denver, Colorado, United States
- Cancer Specialisits of North Florida
Fleming Island, Florida, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Georgia Regents University Hospital
Augusta, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Minnesota Medical Center (ummc)
Minneapolis, Minnesota, United States
- Bozeman Deaconess Health Group
Bozeman, Montana, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- the University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, United States
- Weill Cornell
Brooklyn, New York, United States
- Westchester Medical Center
Hawthorne, New York, United States
- Columbia University Medical Center
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
- Case Western Reserve University (cwru) - University Hospitals Case Medical Center
Cleveland, Ohio, United States
- Ohio State University
Columbus, Ohio, United States
- Oregon Health & Science
Portland, Oregon, United States
- Providence Portland Research Center
Portland, Oregon, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Texas Oncology - Austin Midtown
Austin, Texas, United States
- Baylor University Medical Center
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Cancer Care Centers of South Texas
San Antonio, Texas, United States
- Swedish Medical Center
Seattle, Washington, United States
- Froedtert & Medical College of Wisconson Clinical Cancer Center
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2016
- Primary completion
- 6 Nov 2017
- Completion
- 6 Nov 2017
- Last update posted
- 12 Feb 2019
- Registered enrollment
- 19
- Registry id
- NCT02706899
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.